MedPath

Ciclesonide

Generic Name
Ciclesonide
Brand Names
Alvesco, Omnaris, Zetonna
Drug Type
Small Molecule
Chemical Formula
C32H44O7
CAS Number
126544-47-6
Unique Ingredient Identifier
S59502J185
Background

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Indication

For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Associated Conditions
Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
Clinical Trials
Related News

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Hay Fever
First Posted Date
2006-03-22
Last Posted Date
2016-11-30
Lead Sponsor
AstraZeneca
Target Recruit Count
660
Registration Number
NCT00305487
Locations
🇺🇸

Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States

Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-12-26
Last Posted Date
2005-12-28
Lead Sponsor
Sanofi
Target Recruit Count
450
Registration Number
NCT00270348

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Phase 3
Completed
Conditions
Hay Fever
Perennial Allergic Rhinitis
First Posted Date
2005-12-05
Last Posted Date
2016-11-30
Lead Sponsor
AstraZeneca
Target Recruit Count
102
Registration Number
NCT00261287
Locations
🇺🇸

Altana Pharma/Nycomed, San Antonio, Texas, United States

Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma

Phase 3
Completed
Conditions
Respiratory Tract Diseases
Respiratory Hypersensitivity
Asthma
First Posted Date
2005-11-17
Last Posted Date
2009-04-08
Lead Sponsor
Sanofi
Target Recruit Count
1568
Registration Number
NCT00254956
Locations
🇫🇷

Sanofi-Aventis, Chilly-Mazarin, France

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-09-15
Last Posted Date
2009-04-08
Lead Sponsor
Sanofi
Target Recruit Count
708
Registration Number
NCT00174720
Locations
🇷🇺

Sanofi-Aventis Administrative Office, Moscow, Russian Federation

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-09-15
Last Posted Date
2009-04-08
Lead Sponsor
Sanofi
Target Recruit Count
456
Registration Number
NCT00174733
Locations
🇺🇸

Sanofi-Aventis, Bridgewater, New Jersey, United States

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Phase 3
Completed
Conditions
Perennial Allergic Rhinitis
Allergic Rhinitis
Hay Fever
First Posted Date
2005-09-14
Last Posted Date
2016-12-05
Lead Sponsor
AstraZeneca
Target Recruit Count
106
Registration Number
NCT00163488
Locations
🇺🇸

Altana Pharma/Nycomed, Long Beach, California, United States

Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-09-14
Last Posted Date
2016-11-30
Lead Sponsor
AstraZeneca
Target Recruit Count
120
Registration Number
NCT00163397
Locations
🇨🇳

Altana Pharma/Nycomed, Taipei, Taiwan

Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-09-14
Last Posted Date
2016-12-05
Lead Sponsor
AstraZeneca
Target Recruit Count
750
Registration Number
NCT00163462
Locations
🇿🇦

Altana Pharma/Nycomed, Wynberg, South Africa

Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-09-14
Last Posted Date
2016-11-30
Lead Sponsor
AstraZeneca
Target Recruit Count
630
Registration Number
NCT00163358
Locations
🇪🇸

Altana Pharma/Nycomed, Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy